Belle Mead, NJ, United States of America

Haiqun Tang

USPTO Granted Patents = 15 (Patent Applications = 7)

EPO Patents = 12 (Patent Applications = 12)

Average Co-Inventor Count = 11.0

ph-index = 3

Forward Citations = 29(Granted Patents)

Location History:

Belle Meade, NJ (US) (2020)
Belle Mead, NJ (US) (2008 - 2021)

Company Filing History:

11 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2008-2021

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11207312 - Metallo-beta-lactamase inhibitors and methods of use thereof (2021-12-28),

2. 10544130 - Metallo-beta-lactamase inhibitors (2020-01-28),

3. 10414775 - Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease (2019-09-17),

4. 10414774 - Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease (2019-09-17),

5. 10227331 - Metallo-β-lactamase inhibitors (2019-03-12),

6. 10221163 - Metallo-beta-lactamase inhibitors (2019-03-05),

7. 9839642 - Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors (2017-12-12),

8. 9708336 - Metallo-beta-lactamase inhibitors (2017-07-18),

9. 9586948 - Inhibitors of IRAK4 activity (2017-03-07),

10. 8927559 - [object Object] (2015-01-06),

11. 8569521 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2013-10-29),

12. 8067621 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2011-11-29),

13. 7723342 - Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia (2010-05-25),

14. 7361769 - Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders (2008-04-22),

15. 7348328 - MCH antagonists for the treatment of obesity (2008-03-25),

Title: Haiqun Tang: A Visionary Inventor Pushing Boundaries in Pharmaceutical Innovation

Introduction:

Haiqun Tang, a distinguished inventor based in Belle Mead, NJ, is renowned for his unwavering commitment to innovation and excellence in the realm of pharmaceutical advancements. With an impressive portfolio of 15 patents to his name, Tang has solidified his position as a trailblazer in the field of metallo-beta-lactamase inhibitors.

Latest Patents:

Tang's latest patents revolve around metallo-beta-lactamase inhibitor compounds, catering to the urgent need for innovative solutions in combating antibiotic resistance. These compounds, formulated according to Formula I, demonstrate promising potential in revolutionizing the treatment of bacterial infections. Through strategic combinations with beta-lactam antibiotics and inhibitors, Tang's inventions offer a multifaceted approach to overcoming antibiotic resistance.

Career Highlights:

Having contributed significantly to the industry, Tang has lent his expertise to renowned companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His tenure at these esteemed organizations has been marked by groundbreaking discoveries that have shaped the landscape of pharmaceutical research and development.

Collaborations:

Throughout his career, Tang has collaborated closely with accomplished professionals in the field, including colleagues such as Jing Su and Zhiqiang Zhao. These collaborations have led to synergistic partnerships that have fueled the innovative spirit driving Tang's inventive pursuits.

Conclusion:

In conclusion, Haiqun Tang's dedication to pushing the boundaries of pharmaceutical innovation underscores his status as a visionary inventor at the forefront of technological advancement. His profound impact on the field of metallo-beta-lactamase inhibitors serves as a testament to his relentless pursuit of excellence and unwavering passion for driving positive change in the realm of healthcare.

This text is generated by artificial intelligence and may not be accurate.